Skip to content
S2006Senate2021-2022 SessionSame asA5218

Rebates Go To Patients

Official title

“Requires certain insurance carriers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale”

Sponsor Robert JacksonSD-31Affects Finance
Status
In Senate Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires health insurers to pass on at least 50% of prescription drug rebates to patients at the point of sale.

Why it matters

  1. Direct financial benefit to patients. By requiring insurers to pass through at least 50% of prescription drug rebates at the point of sale, patients could see immediate reductions in their out-of-pocket costs for medications, rather than rebates being used only to lower premiums or kept by insurers.

  2. Redefining how rebate savings are shared. The bill broadens the definition of "rebate" to include price concessions, performance-based rebates, and certain administrative fees, potentially increasing the total amount of savings that might be passed to patients.

  3. Increased transparency (with confidentiality). Insurers must certify annually that they are complying, but actual rebate amounts for specific drugs or manufacturers remain confidential, protecting proprietary business information while still requiring accountability.

  4. Potential market impact. Shifting rebate benefits to the point of sale could change negotiation dynamics between insurers, pharmacy benefit managers, and drug manufacturers, possibly influencing drug pricing strategies and competition in the pharmaceutical market.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Rebates Go To Patients

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Robert Jackson

Senator · Senate District 31

Chair, Civil Service And Pensions

No co-sponsors yet.

History

  1. Referred to insurance
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A5218Assembly

Drug Rebates Go to Patients

In Assembly Committee · Insurance · Sponsor Latrice Walker

Impact 6 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

2006

2021-2022 Regular Sessions

IN SENATE

January 16, 2021

Introduced by Sen. JACKSON -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to requiring individual and small group insurance carriers and group and blanket accident and health carriers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 1 of subsection (e) of section 3231 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C) an insurer shall annually certify to the department that, during the prior benefit year, the insurer made available to enrollees at the point of sale at least a majority (i.e., greater than fifty percent) of the rebates received by such insurer or any third party administering prescription drug benefits on behalf of such insurer.

(i) For purposes of this paragraph, "rebate" means:

(1) negotiated price concessions including but not limited to base rebates and reasonable estimates of any price protection rebates and performance-based rebates that may accrue directly or indirectly to the issuer during the coverage year from a manufacturer, dispensing pharmacy, or other party to the transaction, and

(2) reasonable estimates of any fees and other administrative costs that are passed through to the issuer and serve to reduce the issuer's prescription drug liabilities for the coverage year.

(ii) In providing the certification required under this subparagraph, an issuer shall not publish or otherwise reveal information regarding the actual amount of rebates the issuer received on a product-, manufacturer- or pharmacy-specific basis. Such information is protected as a trade secret, is not a public record as defined in the public officers law and shall not be disclosed directly or indirectly. An insurer shall impose the confidentiality protections of this subparagraph on any third

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02313-01-1

S. 2006 2

parties or vendors with which it contracts that may receive or have access to rebate information.

§ 2. Subsection (b) of section 3221 of the insurance law is amended to read as follows:

(b) (1) No such policy shall be delivered or issued for delivery in this state unless a schedule of the premium rates pertaining to such form shall have been filed with the superintendent.

(2) An insurer shall annually certify to the department that, during the prior benefit year, the insurer made available to enrollees at the point of sale at least a majority (i.e., greater than fifty percent) of the rebates received by such insurer or any third party administering prescription drug benefits on behalf of such insurer.

(A) For purposes of this paragraph, "rebate" means:

(i) negotiated price concessions including but not limited to base rebates and reasonable estimates of any price protection rebates and performance-based rebates that may accrue directly or indirectly to the issuer during the coverage year from a manufacturer, dispensing pharmacy, or other party to the transaction, and

(ii) reasonable estimates of any fees and other administrative costs that are passed through to the issuer and serve to reduce the issuer's prescription drug liabilities for the coverage year.

(B) In providing the certification required under this subsection, an issuer shall not publish or otherwise reveal information regarding the actual amount of rebates the issuer received on a product-, manufacturer- or pharmacy-specific basis. Such information is protected as a trade secret, is not a public record as defined in the public officers law and shall not be disclosed directly or indirectly. An insurer shall impose the confidentiality protections of this subsection on any third parties or vendors with which it contracts that may receive or have access to rebate information.

§ 3. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to requiring individual and small group insurance carriers and group and blanket accident and health carriers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

Purpose

To ensure patients benefit from substantial discounts that exist within the prescription drug supply chain.

Summary of provisions

Section 1 adds a new subparagraph (C) to subsection (e) of Section 3231 of the Insurance Law to require individual and small group carriers to certify that at least a majority (greater than 50%) of prescription drug rebates are provided to patients at the point of sale.

Section 2 amends subsection (b) of Section 3221 of the Insurance Law to require group and blanket accident and health carriers to certify that at least a majority (greater than 50%) of prescription drug rebates are provided to patients at the point of sale.

Section 3 is the effective date.

Justification

The difference between list prices of prescription drugs and the net prices paid by pharmacy benefit managers and health insurers has been growing exponentially in recent years. While many entities benefit from these large negotiated discounts - estimated at $166 billion in 2018 - one group gets the short end of the stick: patients.

As more and more health insurance benefit designs rely on coinsurance and deductibles, patients end up paying cost sharing on the list price of the drug even as their health plan is reaping significant discounts. Unlike negotiated discounts on other services like hospital care, these savings are not shared with patients in the deducible phase of a plan and patients often end up paying more than their health plan for a drug. Plans argue that the discounts are used to lower premiums for everyone, but patients with complex and chronic conditions end up carrying the biggest burden - exactly the opposite of how insurance should work. This bill strikes a careful balance, allowing rebates and discounts to be socialized and keep premiums down to a point, but also making sure some of those significant discounts are passed along to the place they're most important to patients - at the pharmacy counter.

Many health plans have already implemented this option and have marketed this approach as good for patients and "worth it."

Legislative history

2019-2020: S.6489 - Referred to Insurance/A.8310 - Referred to Insurance

State and local fiscal implications

None.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.